Key result
Astragaloside IV reduces infarct size and improves LV function in preclinical ischemic heart disease models.
Why the study?
Does Astragaloside IV improve cardiac function and reduce injury in preclinical models of ischemic heart disease?
Meta-Analysis (n=18)
Does Astragaloside IV improve cardiac function and reduce injury in preclinical models of ischemic heart disease?
Astragaloside IV demonstrates cardioprotective effects in preclinical models of ischemic heart disease through anti-apoptotic, anti-inflammatory, and pro-angiogenic mechanisms.
This systematic review and meta-analysis were conducted to evaluate the therapeutic efficacy of Astragaloside IV (As-IV) in ischemic heart disease based on the preclinical evidence and to correlate the cardioprotective effect with various available mechanisms. This systematic review and meta-analysis were conducted based on the results of a thorough literature search in databases of published papers, such as PubMed, Embase, and Google Scholar. A total of 18 studies that met the inclusion/exclusion criteria were included. The meta-analysis has shown the significant therapeutic efficacy of As-IV on ischemic heart disease. As-IV has decreased the myocardial infarction size, the left ventricular weight indices, the left ventricular internal diameter in systole, and the left ventricular internal diameter in diastole. As-IV has decreased the level of the third type of collagen and the decreased activity of creatine kinase and lactate dehydrogenase. Also, As-IV has markedly decreased the rate of apoptosis and the expression of the proapoptotic markers such as caspase-3 and Bax. The left ventricular systolic pressure, as well as the arterial shortening edge and the ejection fraction, has increased. The levels of the antiapoptotic protein Bcl-2 increased. In addition, As-IV has a powerful anti-inflammatory influence by inhibiting the main markers of inflammation, such as TLR4, IL-1, TNF-α, and TGF-β. As-IV has also caused an effect on angiogenesis by increasing the VEGF level. The results have revealed the As-IV, as a decent universal medicine for ischemic heart disease because of its variety of actions and effectiveness.
No takes yet. Share an insight, caveat, or question.
Greeny et al. (2025) conducted a meta-analysis in Ischemic heart disease (n=18). Astragaloside IV (As-IV) was evaluated on Therapeutic efficacy (myocardial infarction size, left ventricular function, apoptosis, and inflammation markers). In a meta-analysis of 18 preclinical studies, Astragaloside IV demonstrated significant therapeutic efficacy in ischemic heart disease by decreasing myocardial infarction size and improving LV function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: